Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | ZUMA-1: updated data and future prospects

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite Pharma Inc., Santa Monica, CA, presents updated data from the pivotal ZUMA-1 trial (NCT02348216), which used CAR T-cell therapy axicabtagene ciloleucel to treat diffuse large B-cell lymphoma and other B-cell lymphomas. The results from this trial are promising, with an overall response rate of 82%. The strong and durable response observed in a heavily pretreated patient group whose prognosis would otherwise be extremely poor is remarkable, and though significant neurological toxicities were experienced, early intervention meant that they were tolerated well. Mr Rossi concludes by highlighting areas for future progress in this field, including improving safety management through clinical trials, opening up new clinical sites which provide this therapy, and setting up clinical trials which use this therapy in combination with other drugs to improve efficacy.